ESR1 and breast cancer: The blockade of the estrogenic signaling through ERα inhibition using selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs) or aromatase inhibitors (AIs) represented, for many years, the first line approach for hormone-based therapy in patients suffering with ERα-positive BC [15].